

To
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001
Maharashtra, India

Scrip Name : Earkart Limited
Scrip Code : 544549
ISIN : INE1A8F01035

Subject : Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Intimation of Proposed incorporation of Wholly-Owned Subsidiary

Dear Sir / Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ('Listing Regulations'), read with Schedule III of aforesaid regulations and HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, we would like to inform that the Board of Director of the Company in their meeting held today i.e., 29 May 2026, has inter-alia approved the incorporation of a wholly owned subsidiary by the name "**Earkart Pharmaceuticals Private Limited**" and "**Earkart Healthcare Services Private Limited**".

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the Listing Regulations are provided in Annexure A, enclosed herewith.

The same will be made available on the Company's website <https://www.earkart.in>

This is for your information, records and appropriate dissemination.

Thanking You.

Yours faithfully,
For Earkart Limited
(formerly known as "Earkart Private Limited")

Preeti Srivastava
Company Secretary & Compliance Officer
Membership No: A31615

Date : 29 May 2026
Place : Noida

Annexure A
Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Information
a.	Name of the target entity, details in brief such as size, turnover etc.	Name: Earkart Pharmaceuticals Private Limited Proposed Authorised Share Capital: Rs. 1,00,000/- (Rupees One Lakh Only) Proposed Paid up Share Capital: Rs. 1,00,000/- (Rupees One Lakh Only) Turnover: Not Applicable, as the entity is yet to be incorporated.
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The proposed entity would be a wholly-owned Subsidiary (WOS) of the Company and hence once incorporated, the WOS will be a related party of the Company and Other subsidiaries. Save and except what is mentioned above, the Promoters / Promoter Group / Group Companies are not interested in the transaction.
c.	Industry to which the entity being acquired belongs	Pharmaceuticals
d.	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	WOS is being incorporated to manufacture, promote, sale and distribute pharmaceuticals and other related product(s).
e.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f.	Indicative time period for completion of the acquisition	Not Applicable
g.	Nature of consideration - whether cash consideration or share swap and details of the same	100% subscription to initial paid-up share capital Of Rs. 1,00,000/- (Rupees One Lakh only) is in cash.
h.	Cost of acquisition or the price at which the shares are acquired	At face value of Rs.10/- (Rupees Ten) per share.
i.	Percentage of shareholding/ control acquired and/ or number of shares acquired	100% subscription to the share capital of the proposed WOS.
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the proposed WOS is yet to be incorporated.

Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Information
a.	Name of the target entity, details in brief such as size, turnover etc.	<p>Name: Earkart Healthcare Services Private Limited</p> <p>Proposed Authorised Share Capital: Rs. 1,00,000/- (Rupees One Lakh Only)</p> <p>Proposed Paid up Share Capital: Rs. 1,00,000/- (Rupees One Lakh Only)</p> <p>Turnover: Not Applicable, as the entity is yet to be incorporated.</p>
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p>The proposed entity would be a wholly-owned Subsidiary (WOS) of the Company and hence once incorporated, the WOS will be a related party of the Company and Other subsidiaries.</p> <p>Save and except what is mentioned above, the Promoters / Promoter Group / Group Companies are not interested in the transaction.</p>
c.	Industry to which the entity being acquired belongs	Healthcare
d.	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	WOS is being incorporated to provide services in healthcare sector
e.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f.	Indicative time period for completion of the acquisition	Not Applicable
g.	Nature of consideration – whether cash consideration or share swap and details of the same	100% subscription to initial paid-up share capital of Rs. 1,00,000/- (Rupees One Lakh only) is in cash.
h.	Cost of acquisition or the price at which the shares are acquired	At face value of Rs.10/- (Rupees Ten) per share.
i.	Percentage of shareholding/ control acquired and/ or number of shares acquired	100% subscription to the share capital of the proposed WOS.
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the proposed WOS is yet to be incorporated.